Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF

Japanese Journal of Clinical Oncology

Volumn 35, Issue 9, 2005, Pages 507-513

  Bottoni, Ugo ^a   Bonaccorsi, Paola ^b   Devirgiliis, Valeria ^b   Panasiti, Vincenzo ^b   Borroni, Riccardo Giovanni ^b   Trasimeni, Guido ^b   Clerico, Rita ^b   Calvieri, Stefano ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BOLD; Brain metastases; G CSF; Melanoma; Polychemotherapy

Indexed keywords

BLEOMYCIN; DACARBAZINE; GADOLINIUM; GRANULOCYTE COLONY STIMULATING FACTOR; LOMUSTINE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE PAIN; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CONSTIPATION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; ITALY; LEUKOPENIA; MALE; MELANOMA; MYALGIA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; REMISSION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LOMUSTINE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; REMISSION INDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME; VINCRISTINE;

EID: 27644438845     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi141     Document Type: Article

References (38)

1. Rigel DS, Carucci JA. Malignant melanoma: Prevention, early detection and treatment in the 21st century. CA Cancer J Clin 2000;50:215-30.
2. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
3. Garbe C, Buttner P, Bertz J, Burg G, d'Hoedt B, Drepper H, et al. Primary cutaneous melanoma: Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995;75:2484-91.
4. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 2004;22: 2101-7.
5. Seigler HF, Lucas VS, Pickett NJ, Huang AT. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer 1980;46:2346-8.
6. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
8. Kirkwood J, Ibrahim J, Sondak V, et al. Preliminary results of the E1690/ S9111/C9190. US intergroup postoperative adjuvant trial of high dose and low dose IFN alpha 2b (HD1 and LD1) in resected high risk or regional lymph node metastatic melanoma in relation to 10 year update results of E1684. Conference proceedings of the European Society for Medical Oncology (ESMO) Congress, Athens. November 1998 (abstr).
9. Crosby T, Fish R, Coles B, Mason MD. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2000:CD001215.
10. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview. J Exp Clin Cancer Res 2000;19:21-34.
11. York RM, Foltz AT. Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer 1988;61:2183-6.
12. Pyrhonen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992;10:1919-26.
13. Abdel-Wahab Z, Weltz C, Hester D, Pickett N, Vervaert C, Barber JR, et al. A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: Monitoring the humoral immune response. Cancer 1997;80:401-12. Erratum in: 1999;86:1380.
14. Schadendorf D, Czarnetzki B, Wittig B. Interleukin-7, interleukin 12, and GM-CS gene transfer in patients with metastatic melanoma. J Mol Med 1995;73:473-7.
15. Armstrong C, Botella R, Galloway T, Murray N, Kramp J, Song I, et al. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res 1996;56:2191-8.
16. Armstrong C, Galloway T, Spitzler S, Potter L, Botella R, Ansel J. Inhibition of murine melanoma growth by GM-CSF gene transfection is not haplotype specific. J Invest Dermatol 1996;106:857.
17. Armstrong C, Papadopoulos M, Spitzler S, Potter L, Galloway T, Ansel J. Transfection of GM-CSF into melanoma cells inhibits metastatic tumor growth in syngeneic mice. J Invest Dermatol 1996;106:810.
18. Armstrong C, Sarradet D, Potter L, Galloway T, Ansel J. Inhibition of melanoma growth by granulocyte macrophage colony stimulating factor requires CTLA-4 expressing CD4 T cells. J Invest Dermatol, 1997; 108:544.
19. Armstrong CA, Ansel JC. Immunology of malignant melanoma. Photochem Photobiol 1996;63(4):418-20.
20. Armstrong CA, Luger T, Ansel J. Cytokines and malignant melanoma. In: Mukhtar, H, ed. Skin Cancer: Mechanisms and Human Relevance. Boca Raton, FL CRC Press 1995:273-80.
21. Bonaccorsi P, Sarradet MD, Patter LE, Galloway TH, Ansel JC, Armstrong CA. Correlation between in vitro CTL response and in vivo protective immune response in GM-CSF transfected melanomas. J Invest Dermatol 1998;110:519.
22. Hensley C, Spitzler S, McAlpine BE, Lynn M, Ansel JC, Solomon AR, et al. In vivo human melanoma cytokine production: Inverse correlation of GM-CSF production with tumor depth. Exp Dermatol 1998;7:335-41.
23. Chang AE, Sondak VK, Bishop DK, Nickoloff BJ, Mulligan RC, Mule JJ. Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene. Hum Gene Ther 1996;7:773-92.
24. Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858-67.
25. Hoeller C, Jansen B, Heere-Ress E, Pustelnik T, Mossbacher U, Schlagbauer-Wadl H, et al. Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metatsases. J Invest Dermatol 2001;117:371-4.
26. Vaquerano JE, Cadbury P, Treseler P, Sagebiel R, Leong SP. Regression of in-transit melanoma metatsasis of the scalp with intralesional recombinant human granulocyte-macrophages-colony stimulating factor. Arch Dermatol 1999;135:1276-7.
27. Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophages-colony stimulating factor. J Clin Oncol 2000;18:1614-21.
28. Ravaud A, Delaunay M, Chevreau C, Coulon V, Debled M, Bret-Dibat C, et al. Granulocyte-macrophages-colony stimulating factor alone or with dacarbazine in metastatic melanoma: A randomized phase II trial. Br J Cancer 2001;85:1467-71.
29. Golab J, Zagozdon R, Stoklosa T, Kaca A, Dabrowska A, Giermasz A, et al. Granulocyte colony stimulating factor demonstrates antitumor activity in melanoma model in mice. Neoplasma 1998;45:35-9.
30. Golab J, Stoklosa T, Zagodzon R, Kaca A, Giermasz A, Pojda Z, et al. G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in melanoma model in mice. Ann Oncol 1998;9:63-9.
31. Matsumoto Y, Saiki I, Murata J, Okuyama H, Tamura M, Azuma I. Recombinant human granulocyte colony-stimulating factor inhibits the metastasis of hematogenous and non-hematogenous tumors in mice. Int J Cancer 1991;49:444-9.
32. Buter J, Sleijfer DT, Willemse PH, van der Graaf WT, de Vries EG, Schraffordt Koops H, et al. Dose escalation of dacarbazine combined with interferon alpha-2a, G-CSF and ondansetron in patients with metastatic melanoma. Anticancer Res 1994;14:1325-8.
33. Fujita A, Fukuoka S, Takabatake H, Tagaki S, Sekine K. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology 2000;59:291-5.
34. Papadopoulos KP, Balmaceda C, Fetell M, Kaufman E, Vahdat LT, Bruce J, et al. A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors. J Neurooncol 1999;44:155-62.
35. Schabitz WR, Kollmar R, Schwaninger M, Juettler E, Bardutzky J, Scholzke MN, et al. Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke 2003;34:745-51.
36. Stan AC, Walter GF, Welte K, Schneider B, Bona CA, Pietsch T. Expression of granulocyte colony-stimulating factor in recurrent glial tumors is inversely correlated with tumor progression. J Neuroimmunol 1999; 94:66-73.
37. Whalen MJ, Carlos TM, Wisniewski SR, Clark RS, Mellick JA, Marion DW, et al. Effect of neutropenia and granulocyte colony stimulating factor-induced neutrophilia on blood-brain barrier permeability and brain edema after traumatic brain injury in rats. Crit Care Med 2000;28:3710-7.
38. Kollmar R, Schwab S. Granulocyte colony stimulating factor: Just another neuroprotectant? Crit Care Med 2004;32:2357.